Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD

38.32  +0.11 (+0.29%)

After market: 38.5782 +0.26 (+0.67%)

Fundamental Rating

5

TGTX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and the financial health of TGTX get a neutral evaluation. Nothing too spectacular is happening here. TGTX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

TGTX had positive earnings in the past year.
In the past year TGTX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: TGTX reported negative net income in multiple years.
TGTX had a negative operating cash flow in each of the past 5 years.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of TGTX (4.05%) is better than 93.49% of its industry peers.
TGTX has a better Return On Equity (10.52%) than 94.54% of its industry peers.
TGTX's Return On Invested Capital of 6.80% is amongst the best of the industry. TGTX outperforms 94.37% of its industry peers.
Industry RankSector Rank
ROA 4.05%
ROE 10.52%
ROIC 6.8%
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

TGTX has a Profit Margin of 7.11%. This is amongst the best in the industry. TGTX outperforms 92.96% of its industry peers.
The Operating Margin of TGTX (12.74%) is better than 94.54% of its industry peers.
TGTX has a Gross Margin of 88.30%. This is amongst the best in the industry. TGTX outperforms 89.79% of its industry peers.
In the last couple of years the Gross Margin of TGTX has remained more or less at the same level.
Industry RankSector Rank
OM 12.74%
PM (TTM) 7.11%
GM 88.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TGTX is destroying value.
Compared to 1 year ago, TGTX has more shares outstanding
Compared to 5 years ago, TGTX has more shares outstanding
TGTX has a worse debt/assets ratio than last year.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

TGTX has an Altman-Z score of 8.25. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.25, TGTX belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
TGTX has a Debt/Equity ratio of 1.10. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.10, TGTX is not doing good in the industry: 78.52% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF N/A
Altman-Z 8.25
ROIC/WACC0.65
WACC10.41%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

TGTX has a Current Ratio of 6.25. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX's Current ratio of 6.25 is fine compared to the rest of the industry. TGTX outperforms 65.32% of its industry peers.
A Quick Ratio of 5.03 indicates that TGTX has no problem at all paying its short term obligations.
TGTX's Quick ratio of 5.03 is in line compared to the rest of the industry. TGTX outperforms 55.81% of its industry peers.
Industry RankSector Rank
Current Ratio 6.25
Quick Ratio 5.03
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

8

3. Growth

3.1 Past

TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1300.00%, which is quite impressive.
Looking at the last year, TGTX shows a very strong growth in Revenue. The Revenue has grown by 40.80%.
Measured over the past years, TGTX shows a very strong growth in Revenue. The Revenue has been growing by 364.59% on average per year.
EPS 1Y (TTM)1300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
Revenue 1Y (TTM)40.8%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%146.04%

3.2 Future

TGTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.07% yearly.
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.10% yearly.
EPS Next Y577.57%
EPS Next 2Y276.65%
EPS Next 3Y164.44%
EPS Next 5Y103.07%
Revenue Next Year76.9%
Revenue Next 2Y56.34%
Revenue Next 3Y44.55%
Revenue Next 5Y37.1%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 273.71, TGTX can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 91.73% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of TGTX to the average of the S&P500 Index (28.29), we can say TGTX is valued expensively.
TGTX is valuated quite expensively with a Price/Forward Earnings ratio of 40.40.
Based on the Price/Forward Earnings ratio, TGTX is valued cheaper than 92.08% of the companies in the same industry.
TGTX is valuated expensively when we compare the Price/Forward Earnings ratio to 21.08, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 273.71
Fwd PE 40.4
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200 250

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 92.25% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 138.61
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

TGTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of TGTX may justify a higher PE ratio.
TGTX's earnings are expected to grow with 164.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y276.65%
EPS Next 3Y164.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TG THERAPEUTICS INC

NASDAQ:TGTX (4/17/2025, 8:00:00 PM)

After market: 38.5782 +0.26 (+0.67%)

38.32

+0.11 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-06 2025-05-06
Inst Owners63.58%
Inst Owner Change0%
Ins Owners10.03%
Ins Owner Change2.96%
Market Cap6.02B
Analysts80
Price Target43.28 (12.94%)
Short Float %18.41%
Short Ratio9.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.82%
Min EPS beat(2)-33.53%
Max EPS beat(2)77.18%
EPS beat(4)2
Avg EPS beat(4)34.31%
Min EPS beat(4)-92.18%
Max EPS beat(4)185.79%
EPS beat(8)5
Avg EPS beat(8)81.62%
EPS beat(12)8
Avg EPS beat(12)57.46%
EPS beat(16)8
Avg EPS beat(16)38.4%
Revenue beat(2)2
Avg Revenue beat(2)3.38%
Min Revenue beat(2)0.65%
Max Revenue beat(2)6.12%
Revenue beat(4)4
Avg Revenue beat(4)7.51%
Min Revenue beat(4)0.65%
Max Revenue beat(4)13.96%
Revenue beat(8)7
Avg Revenue beat(8)50.43%
Revenue beat(12)8
Avg Revenue beat(12)33.46%
Revenue beat(16)10
Avg Revenue beat(16)20.87%
PT rev (1m)5.32%
PT rev (3m)4.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40.36%
EPS NY rev (1m)6.49%
EPS NY rev (3m)-3.5%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)6.24%
Revenue NY rev (1m)1.1%
Revenue NY rev (3m)3.1%
Valuation
Industry RankSector Rank
PE 273.71
Fwd PE 40.4
P/S 18.29
P/FCF N/A
P/OCF N/A
P/B 27.07
P/tB 27.07
EV/EBITDA 138.61
EPS(TTM)0.14
EY0.37%
EPS(NY)0.95
Fwd EY2.48%
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS2.09
BVpS1.42
TBVpS1.42
PEG (NY)0.47
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.05%
ROE 10.52%
ROCE 8.61%
ROIC 6.8%
ROICexc 18.82%
ROICexgc 18.82%
OM 12.74%
PM (TTM) 7.11%
GM 88.3%
FCFM N/A
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score4
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 1.1
Debt/FCF N/A
Debt/EBITDA 5.82
Cap/Depr 66.18%
Cap/Sales 0.01%
Interest Coverage 2.27
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.25
Quick Ratio 5.03
Altman-Z 8.25
F-Score4
WACC10.41%
ROIC/WACC0.65
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1300%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
EPS Next Y577.57%
EPS Next 2Y276.65%
EPS Next 3Y164.44%
EPS Next 5Y103.07%
Revenue 1Y (TTM)40.8%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%146.04%
Revenue Next Year76.9%
Revenue Next 2Y56.34%
Revenue Next 3Y44.55%
Revenue Next 5Y37.1%
EBIT growth 1Y103.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year584.73%
EBIT Next 3Y125.12%
EBIT Next 5YN/A
FCF growth 1Y-29.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.98%
OCF growth 3YN/A
OCF growth 5YN/A